Combination of intravitreal bevacizumab and erythropoietin vs intravitreal bevacizumab alone for refractory diabetic macular edema: A randomized double-blind clinical trial
Graefe's Archive for Clinical and Experimental Ophthalmology Nov 08, 2019
Entezari M, Flavarjani ZK, Ramezani A, et al. - Researchers examined the efficacy of three intravitreal bevacizumab (IVB) injections alone or in combination with intravitreal erythropoietin (EPO) for the treatment of refractory diabetic macular edema (DME). They conducted a randomized double-blind clinical trial enrolling 48 eyes of 34 diabetic patients with refractory DME. Either 3 monthly injections of 0.05 cc (1.25 mg) IVB plus 0.05 cc (1,000 unit) EPO or 0.05 cc (1.25 mg) IVB alone was administered in the eyes. Both groups exhibited insignificant mean best-corrected visual acuity changes up to 4 and 6 months. Outcomes revealed no additional effect of intravitreal erythropoietin to IVB in the treatment of refractory DME in the short term.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries